whatpeptidestostack
← Compound library
MT-2
A synthetic melanocortin receptor agonist studied for skin pigmentation. The human records here are case reports of harm after unregulated use, and the benefit signals come from animal work.
The basics
| Human protocol on record | 1 figures |
|---|---|
| Animal or laboratory figures | 4 |
| Published records retrieved | 32 |
| Registered trials | 11 |
| Certificate of analysis | Published by the partner |
| Regulatory status | Research-grade material, no approved human use |
1. The protocol on record
Hard disclaimer. Figures below are transcribed from a published study or an approved label exactly as the source states them. They record what researchers administered in a trial population, not instructions for any person, and none of it is adjusted to you. Most compounds here have no approved human use. Do not act on any of it without a licensed prescriber who knows your history.
Amounts and schedules, human record
| Phase or model | Amount | Frequency | Timing | Route | Duration | Source |
|---|---|---|---|---|---|---|
| Case report, one adult male, self-administered Internet-purchased product | 6 mg | single injection | not stated | subcutaneous | single dose | source |
Animal and laboratory models (not human figures)
| Phase or model | Amount | Frequency | Timing | Route | Duration | Source |
|---|---|---|---|---|---|---|
| Anaesthetized rat erection model, inducer and facilitator experiments | 0.1, 0.3 and 1 mg/kg | not stated | not stated | intravenous (i.v.) | not stated | source |
| Anaesthetized rat erection model, central microinjection | 0.1 and 1 microg | not stated | not stated | microinjection into the paraventricular nucleus of the hypothalamus | not stated | source |
| Anaesthetized rat erection model, spinal delivery | 0.2 microg | not stated | not stated | intrathecal (i.t.) at the L6-S1 level | not stated | source |
| Anaesthetized rat erection model, local injection | 1 microg | not stated | not stated | injection within the corpus cavernosum | not stated | source |
Half-life and why the schedule looks like that
Not stated in the cited record. No cited source states a half-life, clearance, or duration of action for melanotan II, and no cited source states a dosing frequency for it. The only human administration in the record is a single subcutaneous injection of 6 mg in a case report of toxicity, not a dosing schedule (PMID 23121206). One Phase 2 trial of melanotan II as an adjunct to NB-UVB phototherapy in vitiligo is listed as recruiting, but its record carries no amount, frequency, route, or duration (NCT07437560).
Handling and storage
- Lyophilised storage: Not stated in the cited record. - Storage after reconstitution: Not stated in the cited record. - Temperature: Not stated in the cited record. - Light: Not stated in the cited record. - Stability duration: Not stated in the cited record. No approved label exists for this compound in the cited record, so no label storage statement can be written here.
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Open the interactive builder for reconstitution maths and a calendar →
2. Safety and harm reduction
Reported adverse effects
| Effect | How often reported | Population | Source |
|---|---|---|---|
| Systemic toxicity with sympathomimetic excess: diffuse body aches, sweating, anxiety, tachycardia (heart rate 130 bpm, peaking at 146 bpm), blood pressure 151/85 mmHg, mydriasis, diaphoresis, diffuse muscle tremors | Single case report (one patient) | Case report, one 39-year-old male, two hours after subcutaneous injection of 6 mg of Internet-purchased melanotan II | source |
| Rhabdomyolysis with renal involvement (CPK rising to 17773 IU/L, creatinine 2.25 mg/dL, troponin 0.23 ng/mL; ICU admission, discharge after 3 days) | Single case report (one patient) | Same case report as above | source |
| Renal infarction, attributed to melanotan II; the authors state renal infarction is potentially life-threatening, and that rhabdomyolysis and renal failure with melanotan II have been described previously | Single case report (one patient) | Case report and literature review, one patient | source |
| Acute ischemic priapism after subcutaneous injection, not resolving with aspiration, irrigation, or intracavernous phenylephrine, and requiring operative management | Described by the source as rare; the source states priapism after melanotan II injection had been reported in the literature only twice before | Case report, one patient | source |
Cautions stated in the literature
- Melanotan II is sold through an unregulated, illicit market and little is known about its use; users inject it subcutaneously to stimulate a tan. ([PMID 30142729](https://pubmed.ncbi.nlm.nih.gov/30142729/))
- Analysis of vials sold illegally online found actual contents of 4.32 to 8.84 mg per vial against a claimed 10 mg, and unknown impurities of 4.1 to 5.9 percent in vials from two of three shops; the authors state users may be exposed to a range of potential harms given illicit manufacture, distribution, and supply. ([PMID 24771717](https://pubmed.ncbi.nlm.nih.gov/24771717/))
- A review of falsified biotechnology drugs, which includes melanotan II among image-enhancing polypeptides, states that end-users of falsified products have no guarantee of safety or efficacy; reports describe the wrong active ingredient, the wrong dosage, or absence of the active ingredient, as well as adverse health effects from toxic contaminations and product or process related impurities. ([PMID 30165334](https://pubmed.ncbi.nlm.nih.gov/30165334/))
- A qualitative study of online forum discussions states that clinicians should be aware of risks in relation to pigmented skin lesions, and names other medical hazards of melanotan II use: transmission of infectious diseases, use of potentially contaminated products, polypharmacy, and sunbed exposure. ([PMID 34464955](https://pubmed.ncbi.nlm.nih.gov/34464955/))
- The renal infarction case review states that in the mechanism of renal injury with melanotan II, thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered. ([PMID 31953620](https://pubmed.ncbi.nlm.nih.gov/31953620/))
- The priapism case report states that future therapeutic applications of these agents and updated management guidelines should consider priapism as a possible side effect. ([PMID 33460908](https://pubmed.ncbi.nlm.nih.gov/33460908/))
Stop and get help
- A severe or worsening reaction after use.
- Signs of an allergic reaction, such as rash, itching, swelling of the face, lips, tongue or throat, or difficulty breathing.
- Signs of injection-site infection, such as spreading redness, warmth, swelling, pain, pus, or fever.
- Anything unexpected that persists or does not resolve.
MT-2 at Peptara Labs
Open the MT-2 pageRead the third-party certificate of analysis before anything else. Research-grade material, research use only.